Barbexaclone
Chemical compound
From Wikipedia, the free encyclopedia
Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[2] It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[3] had not yet been confirmed nor denied in controlled trials.
| |
| Combination of | |
|---|---|
| Phenobarbital | Barbiturate |
| Levopropylhexedrine | Sympathomimetic |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.022.278 |
  (what is this?) (verify) | |
Potency
100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[2]
